AU2015272115B2 - The use of dextran sulfate having an average molecular weight below 10000 Da for inducing angiogenisis in a subject - Google Patents

The use of dextran sulfate having an average molecular weight below 10000 Da for inducing angiogenisis in a subject Download PDF

Info

Publication number
AU2015272115B2
AU2015272115B2 AU2015272115A AU2015272115A AU2015272115B2 AU 2015272115 B2 AU2015272115 B2 AU 2015272115B2 AU 2015272115 A AU2015272115 A AU 2015272115A AU 2015272115 A AU2015272115 A AU 2015272115A AU 2015272115 B2 AU2015272115 B2 AU 2015272115B2
Authority
AU
Australia
Prior art keywords
dextran sulfate
subject
ischemia
pharmaceutically acceptable
acceptable derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015272115A
Other languages
English (en)
Other versions
AU2015272115A1 (en
Inventor
Adam Bruce
Lars Bruce
Anders WAAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TX Medic AB
Original Assignee
TX Medic AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE1451120A external-priority patent/SE538144C2/sv
Application filed by TX Medic AB filed Critical TX Medic AB
Priority claimed from PCT/SE2015/050677 external-priority patent/WO2015190989A1/en
Publication of AU2015272115A1 publication Critical patent/AU2015272115A1/en
Application granted granted Critical
Publication of AU2015272115B2 publication Critical patent/AU2015272115B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AU2015272115A 2014-06-12 2015-06-11 The use of dextran sulfate having an average molecular weight below 10000 Da for inducing angiogenisis in a subject Active AU2015272115B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
SE1450729 2014-06-12
SE1450729-7 2014-06-12
SE1451120-8 2014-09-22
SE1451120A SE538144C2 (sv) 2014-06-12 2014-09-22 Use of dextran sulfate for inducing angiogenesis
SE1451540 2014-12-15
SE1451540-7 2014-12-15
PCT/SE2015/050677 WO2015190989A1 (en) 2014-06-12 2015-06-11 The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject

Publications (2)

Publication Number Publication Date
AU2015272115A1 AU2015272115A1 (en) 2016-12-22
AU2015272115B2 true AU2015272115B2 (en) 2019-01-17

Family

ID=57575349

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015272115A Active AU2015272115B2 (en) 2014-06-12 2015-06-11 The use of dextran sulfate having an average molecular weight below 10000 Da for inducing angiogenisis in a subject

Country Status (21)

Country Link
US (2) US10485817B2 (es)
EP (1) EP3154551B1 (es)
JP (1) JP6557683B2 (es)
KR (1) KR102015197B1 (es)
CN (1) CN106573012B (es)
AU (1) AU2015272115B2 (es)
BR (1) BR112016029008B1 (es)
CA (1) CA2951686C (es)
DK (1) DK3154551T3 (es)
EA (1) EA032569B1 (es)
ES (1) ES2705069T3 (es)
HR (1) HRP20190051T1 (es)
IL (1) IL249436B (es)
MX (1) MX363122B (es)
MY (1) MY178989A (es)
NZ (1) NZ727008A (es)
PH (1) PH12016502435B1 (es)
PL (1) PL3154551T3 (es)
PT (1) PT3154551T (es)
SG (1) SG11201610142PA (es)
ZA (1) ZA201700134B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE538503C2 (en) * 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
CN107137421A (zh) * 2017-05-25 2017-09-08 青岛市中心医院 硫酸葡聚糖在制备抑制角膜血管新生药物中的应用
JP2020533281A (ja) * 2017-09-08 2020-11-19 ティーエックス メディック エービー デキストラン硫酸の新規使用
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047848A1 (en) * 2002-11-28 2004-06-10 Prophymed Ab New use of dextran sulfate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5945547B2 (ja) 1977-01-31 1984-11-07 豊田合成株式会社 ステアリングホイ−ル
DE3634392A1 (de) 1986-10-09 1988-04-14 Knoll Ag Verwendung polysulfatierter niedermolekularer dextransulfate
US5135920A (en) 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
JPH02223525A (ja) 1988-11-16 1990-09-05 Takeda Chem Ind Ltd 血管新生阻害剤
IT1264530B (it) * 1992-07-31 1996-10-02 Crinos Industria Farmaco Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
CA2305726A1 (en) * 1997-10-07 1999-04-15 Regents Of The University Of California Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine
US6106554A (en) * 1999-02-25 2000-08-22 Bausch & Lomb Surgical, Inc. Intraocular lens implants for the prevention of secondary cataracts
US20030171287A1 (en) 2000-06-27 2003-09-11 Ryuichi Morishita Medicinal compositions for angiogenic therapy
JP5030124B2 (ja) * 2000-12-21 2012-09-19 竜一 森下 血管新生療法用医薬組成物
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
JP2006134692A (ja) * 2004-11-05 2006-05-25 Toppan Printing Co Ltd リチウム電池用外装材
EP1900374B1 (en) 2005-06-16 2014-03-12 Takayuki Shindo Angiogenetic agent containing adrenomedulin as the active ingredient
WO2008134430A1 (en) * 2007-04-24 2008-11-06 Novelmed Therapeutics Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
JP5612279B2 (ja) * 2009-06-26 2014-10-22 日本合成化学工業株式会社 心筋梗塞非ヒト動物モデル及びその作製方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004047848A1 (en) * 2002-11-28 2004-06-10 Prophymed Ab New use of dextran sulfate

Also Published As

Publication number Publication date
KR20170045195A (ko) 2017-04-26
EA032569B1 (ru) 2019-06-28
CA2951686C (en) 2019-05-21
MX2016016312A (es) 2017-08-28
PT3154551T (pt) 2019-01-18
AU2015272115A1 (en) 2016-12-22
MX363122B (es) 2019-03-11
PL3154551T3 (pl) 2019-05-31
CN106573012A (zh) 2017-04-19
EP3154551A1 (en) 2017-04-19
JP2017518322A (ja) 2017-07-06
MY178989A (en) 2020-10-26
PH12016502435A1 (en) 2017-03-06
US20170151275A1 (en) 2017-06-01
IL249436B (en) 2019-07-31
US10485817B2 (en) 2019-11-26
IL249436A0 (en) 2017-02-28
PH12016502435B1 (en) 2017-03-06
KR102015197B1 (ko) 2019-08-27
HRP20190051T1 (hr) 2019-03-08
NZ727008A (en) 2020-05-29
JP6557683B2 (ja) 2019-08-07
US10925890B2 (en) 2021-02-23
BR112016029008A2 (pt) 2017-08-22
EP3154551B1 (en) 2018-10-10
US20190381090A1 (en) 2019-12-19
ES2705069T3 (es) 2019-03-21
CN106573012B (zh) 2020-02-28
SG11201610142PA (en) 2017-01-27
CA2951686A1 (en) 2015-12-17
DK3154551T3 (en) 2019-01-28
EA201692555A1 (ru) 2017-04-28
EP3154551A4 (en) 2017-12-27
BR112016029008B1 (pt) 2023-05-02
ZA201700134B (en) 2018-04-25

Similar Documents

Publication Publication Date Title
US10925890B2 (en) Use of dextran sulfate
US7785632B2 (en) Thyroid hormone analogs and methods of use
Xu et al. Sustained-release of FGF-2 from a hybrid hydrogel of heparin-poloxamer and decellular matrix promotes the neuroprotective effects of proteins after spinal injury
Fowell et al. Arteriovenous malformations of the head and neck: current concepts in management
JP5908527B2 (ja) 慢性虚血における亜硝酸塩の使用
WO2015190989A1 (en) The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
WO2018157773A1 (zh) 一种促进创伤后组织修复与再生的修复肽及其应用
US20180221403A1 (en) New use of dextran sulfate
JP2006521405A (ja) 発作回復におけるエリトロポイエチンの使用
JP6708869B2 (ja) 神経系疾患治療剤
KR20180055877A (ko) 허혈성 조직으로 구리를 운반하기 위한 트리엔틴의 용도
Kumar et al. Novel formulation approaches used for the management of osteoarthritis: a recent review
JP6180417B2 (ja) 心不全またはニューロン損傷の治療剤製造のための化合物の使用
CA2905650A1 (en) Compostions and methods for enhancing the therapeutic potential of stem cells
CN109641001A (zh) 用于治疗缺血性溃疡和伸展疤痕的组合物
TWI327473B (en) Composition for treating a cerebrovascular disease and a method for increasing expression of erythropoietin
SE538144C2 (sv) Use of dextran sulfate for inducing angiogenesis
CN108685896B (zh) 千层纸素a在制备治疗和/或预防慢性周围血管闭塞性疾病药物中的用途
KR20220041315A (ko) 뇌졸중 치료용 세포치료제
Herz et al. The effect of the adrenocorticotropin-(4-9) analogue, ORG 2766, and of dizolcipine (MK-801) on infarct volume in rat brain
TW201023878A (en) Non-surgical improvement of scars
JP2008230968A (ja) 脳梗塞治療用の医薬

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)